Research Article
The Incidence and Risk Factors of Hip Fracture after Liver Transplantation (LT): A Nationwide Population-Based Study
Table 3
Comparisons of liver recipients with and without hip fractures.
| | Variable | Liver transplant | Crude OR (95% CI) | Adjusted OR (95% CI) | | Hip fracture (−) | Hip fracture (+) | | N = 2184 (%) | N = 17 (%) |
| | Age | | <45 | 475 (21.7) | 1 (5.9) | Ref | Ref | | 45–64 | 1572 (72) | 11 (64.7) | 3.32 (0.43–25.8) | 2.79 (0.34–22.65) | | ≧65 | 137 (6.3) | 5 (29.4) | 17.34 (2.01–149) | 14.64 (1.47–145) | | Sex | | Female | 558 (25.5) | 4 (23.5) | Ref | Ref | | Male | 1626 (74.5) | 13 (76.5) | 1.12 (0.36–3.43) | 1.73 (0.49–6.13) | | Comorbidities | | CAD | 289 (13.2) | 3 (17.6) | 1.41 (0.40–4.92) | 0.38 (0.04–3.19) | | DM | 539 (24.7) | 7 (41.2) | 2.14 (0.81–5.64) | 1.38 (0.49–3.91) | | Epilepsy | 29 (1.3) | 0 (0) | — | — | | Hypertension | 711 (32.6) | 10 (58.8) | 2.96 (1.12–7.81) | 2.15 (0.73–6.30) | | Osteoporosis | 140 (6.4) | 0 (0) | — | — | | Stroke | 69 (3.2) | 1 (5.9) | 1.92 (0.25–14.7) | 1.80 (0.21–15.29) | | ESRD | 28 (1.3) | 0 (0) | — | — | | HBV infection | 1469 (67.3) | 8 (47.1) | 0.43 (0.17–1.13) | 0.43 (0.14–1.31) | | HCV infection | 621 (28.4) | 9 (52.9) | 2.83 (1.09–7.37) | 1.99 (0.66–5.96) | | Steroid | 2044 (93.6) | 17 (100.0) | — | — | | Immunosuppressive agents | | Tacrolimus | 167 (7.65) | 1 (5.88) | 0.76 (0.10–5.73) | 0.46 (0.05–4.24) | | Everolimus | 31 (1.42) | 1 (5.88) | 4.34 (0.56–33.8) | 2.63 (0.29–23.8) | | MMF | 366 (16.8) | 3 (17.7) | 1.06 (0.30–3.72) | 1.32 (0.33–5.27) | | Cyclosporin | 81(3.71) | 0 (0.00) | — | — |
|
|
CI: confidence interval; CAD: coronary artery disease; DM: diabetes mellitus; ESRD: end-stage renal disease; HBV: hepatitis B virus; HCV: hepatitis C virus infection; MMF: mycophenolate mofetil.
|
